

State of Oklahoma SoonerCare Tevimbra™ (tislelizumab-jsgr) Prior Authorization Form

Member Name:	Date of Birth:	Member ID#:
Drug Information		
Physician billing (HCPCS code:) Start Date (or date of next dose):		
Dose:Regimen:		
Billing Provider Information		
	Provider Name:	
Provider Phone: Provider Fax:		
Prescriber Information		
Prescriber NPI:	ber NPI: Prescriber Name:	
Prescriber Phone:	Prescriber Fax:	Specialty:
Criteria Criteria		
For Initial Authorization: 1. Please indicate the diagnosis and information: Esophageal Cancer A. Is diagnosis unresectable or metastatic esophageal squamous cell carcinoma (ESCC)? Yes No B. Will tislelizumab-jsgr be used after disease progression on prior systemic chemotherapy? Yes No C. Has member previously failed other PD-1 or PD-L1 inhibitors? Yes No Other: Additional Information:		
For Continued Authorization: 1. Date of last dose: 2. Does member have any evidence of progressive disease while on tislelizumab-jsgr therapy? Yes No 3. Has member experienced any adverse drug reactions related to tislelizumab-jsgr therapy? Yes No If yes, please specify adverse reactions: Additional Information:		
Prescriber Signature:		Date:
I certify that the indicated treatment is medically necessary and all information is true and correct to the best of my knowledge. Please do not send in chart notes. Specific information will be requested if necessary. Failure to complete this		

Fax completed prior authorization request form to 888-601-8461 or submit Electronic Prior Authorization through CoverMyMeds® or SureScripts. All requested data must be provided. Pharmacy Coverage Guidelines are available at AetnaBetterHealth.com/Oklahoma.

form in full will result in processing delays.

CONFIDENTIALITY NOTICE

This document, including any attachments, contains information which is confidential or privileged. If you are not the intended recipient, be aware that any disclosure, copying, distribution, or use of the contents of this information is prohibited. If you have received this document in error, please notify the sender immediately by telephone to arrange for the return of the transmitted documents or to verify their destruction.

Pharm – 266 4/19/2024